nach oben

Journal of Neuro-Oncology

Erschienen in:

09.10.2020 | Introduction

Management considerations for malignant tumors of the skull base

verfasst von: Franco DeMonte

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Excerpt

The last two decades have brought refinements in diagnostic imaging, instrumentation, microvascular reconstruction and an improved overall appreciation of the anatomy of the skull base, both open and endoscopic. These refinements have extended the boundaries of tumor resection and have obviated the need for adjuvant therapies in some patients with benign or low-grade tumors. In patients with high-grade malignancies, however, a carefully constructed multimodal treatment plan, incorporating surgery, radiation therapy and chemotherapy, is necessary in order to maximize patient outcome. …

Cohen ZR, Marmor E, Fuller GN, DeMonte F (2002) Misdiagnosis of olfactory neuroblastoma. Neurosurg Focus 12(5):1–6CrossRef

Cohen ZR, Marmor E, Fuller GN, DeMonte F (2002) Misdiagnosis of olfactory neuroblastoma. Neurosurg Focus 12(5):e3CrossRef

Perez-Cruet MJ, Burke JM, Weber R, DeMonte F (1998) Aggressive fibromatosis involving the cranial base in children. Neurosurgery 43(5):1096–1102CrossRef

Austin JR, Cebrun H, Kershisnik MM, El-Naggar AK, Garden AS, DeMonte F, Ginsberg LE, Lippman SM, Goepfert H (1996) Olfactory neuroblastoma and neuroendocrine carcinoma of the anterior skull base: treatment results at the M.D. Anderson Cancer Center. Skull Base Surg 6(1):1–8CrossRef

Chamoun RB, Suki D, DeMonte F (2012) Surgical management of cranial base metastases. Neurosurgery 70(4):802–809CrossRef

DeMonte F (2007) Soft tissue sarcomas of the skull base: time for a new paradigm. Cancer 110(5):939–940CrossRef

Diaz EM, Johnigan RH, Pero C, El-Naggar AK, Roberts DB, Barker JL, DeMonte F (2005) Olfactory neuroblastoma: the 22-year experience at one comprehensive cancer center. Head Neck 27(2):138–149CrossRef

Esmaeli B, Golio D, Kies M, DeMonte F (2006) Surgical management of locally advanced adenoid cystic carcinoma of the lacrimal gland. Ophthal Plast Reconstr Surg 22(5):366–370CrossRef

Lupinetti AD, Roberts DB, Williams MD, Kupferman ME, Rosenthal DI, Demonte F, El-Naggar A, Weber RS, Hanna EY (2007) Sinonasal adenoid cystic carcinoma: the MD Anderson Cancer Center experience. Cancer 110(12):2726–2731CrossRef

10.

Choi KN, Rotman M, Aziz H et al (1997) Concomitant infusion of cisplatin and hyperfractionated radiotherapy for locally advanced nasopharyngeal and paranasal sinus tumors. Int J Radiat Oncol Biol Phys 39:823–829CrossRef

11.

Lee MM, Vokes EE, Rosen A et al (1999) Multimodality therapy in advanced paranasal sinus carcinoma: superior long-term results. Cancer J Sci Am 5:219–223PubMed

12.

Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM Jr, Haddad RI (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357(17):1705–1715CrossRef

13.

Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357(17):1695–1704CrossRef

14.

Hanna EY, Cardenas AD, DeMonte F, Roberts D, Kupferman M, Weber R, Rosenthal D, Kies M (2011) Induction chemotherapy for advanced squamous cell carcinoma of the paranasal sinuses. Arch Otolaryngol Head Neck Surg 137(1):78–81CrossRef

15.

Righi PD, Francis F, Aron BS et al (1996) Sinonasal undifferentiated carcinoma: a 10-year experience. Am J Otolaryngol 17:167–171CrossRef

16.

Diaz EM, Kies MS (2001) Chemotherapy for skull base cancers. Otolaryngol Clin North Am 34(6):1079–1085CrossRef

17.

Amit M, Abdelmeguid AS, Watcherporn T, Takahashi H, Tam S, Bell D, Ferrarotta R, Glisson B, Kupferman ME, Roberts DB, Su SY, Raza SM, DeMonte F, Hanna EY (2019) Induction chemotherapy response as a guide for treatment optimization in sinonasal undifferentiated carcinoma. J Clin Oncol 37:504–512CrossRef

18.

Ordonez NG, Mackay B (1993) Neuroendocrine tumors of the nasal cavity. Pathol Annu 28:77–111PubMed

19.

Bhattacharyya N, Thornton AF, Joseph MP, Goodman ML, Amrein PC (1997) Successful treatment of esthesioneuroblastoma and neuroendocrine carcinoma with combined chemotherapy and proton radiation. Results in 9 cases. Arch Otolaryngol Head NeckSurg 123(1):34–40CrossRef

20.

Likhacheva A, Rosenthal DI, Hanna E, Kupferman M, Demonte F, El-Naggar AK (2011) Sinonasal neuroendocrine carcinoma: impact of differentiation status on response and outcome. Head Neck Oncol 3:32CrossRef

21.

Mitchell EH, Diaz A, Yilmaz T, Roberts D, Levine N, Demonte F, Hanna EY, Kupferman ME (2011) Multimodality treatment for sinonasal neuroendocrine carcinoma. Head Neck. https://doi.org/10.1002/hed.21940CrossRefPubMed

22.

Prabhu SS, Diaz E, Sturgis EM, Myers JN, Suki D, Demonte F (2004) Section on tumors: Mahaley Clinical Research Award: primary sarcomas of the skull base: an analysis of 63 cases. Clin Neurosurg 51:340–342PubMed

23.

Sisson GA Sr, Toriumi DM, Atiyah R (1989) Paranasal sinus malignancy: a comprehensive update. Laryngoscope 99(2):143–150CrossRef

24.

Sundaresan N, Shah JP (1988) Craniofacial resection for anterior skull base tumors. Head Neck 10(4):219–224CrossRef

25.

Cantu G, Solero CL, Mariani L et al (1999) Anterior craniofacial resection for malignant ethmoid tumors—a series of 91 patients. Head Neck 21(3):185–191CrossRef

26.

Danks RA, Kaye AH, Millar H et al (1994) Craniofacial resection in the management of paranasal sinus cancer. J Clin Neuroscience 1(2):111–117CrossRef

27.

Ganly I, Patel SG, Singh B, Kraus DH, Bridger PG, Cantu G, Cheesman A, De Sa G, Donald P, Fliss DM, Gullane P, Janecka I, Kamata SE, Kowalski LP, Levine PA, Medina Dos Santos LR, Pradhan S, Schramm V, Snyderman C, Wei WI, Shah JP (2005) Craniofacial resection for malignant paranasal sinus tumors: report of an International Collaborative Study. Head Neck 27(7):575–584CrossRef

28.

Janecka IP, Sen C, Sekhar LN et al (1994) Cranial base surgery: results in 183 patients. Otolaryngol Head Neck Surg 110:539–546CrossRef

29.

Lund VJ, Howard DJ, Wei WI et al (1998) Craniofacial resection for tumors of the nasal cavity and paranasal sinuses: a 17-year experience. Head Neck 20(2):97–105CrossRef

30.

Patel SG, Singh B, Polluri A, Bridger PG, Cantu G, Cheesman AD, deSa GM, Donald P, Fliss D, Gullane P, Janecka I, Kamata SE, Kowalski LP, Kraus DH, Levine PA, dos Santos LR, Pradhan S, Schramm V, Snyderman C, Wei WI, Shah JP (2003) Craniofacial surgery for malignant skull base tumors: report of an international collaborative study. Cancer 98(6):1179–1187CrossRef

31.

Shah JP, Kraus DH, Bilsky MH et al (1997) Craniofacial resection for malignant tumors involving the anterior skull base. Arch Otolaryngol Head Neck Surg 123(12):1312–1317CrossRef

32.

Feiz-Erfan I, Suki D, Hanna E, DeMonte F (2007) Prognostic significance of transdural invasion of cranial base malignancies in patients undergoing craniofacial resection. Neurosurgery 61(6):1178–1185CrossRef

33.

Hentschel SJ, Nader R, Suki D, Dastgir A, Callender DL, DeMonte F (2004) Craniofacial resections in the elderly: an outcome study. J Neurosurg 101(6):935–943CrossRef

34.

Hanna E, DeMonte F, Ibrahim S, Roberts D, Levine N, Kupferman M (2009) Endoscopic resection of sinonasal cancers with and without craniotomy: oncologic results. Arch Otolaryngol Head Neck Surg 135(12):1219–1224CrossRef

35.

Abdelmeguid AS, Raza S, Su SY, Kupferman M, Roberts D, DeMonte F, Hanna EY (2020) Endoscopic resection of sinonasal malignancies. Head Neck 42:645–652CrossRef

36.

DeMonte F (2001) Functional outcomes in skull base surgery. What is acceptable? Clin Neurosurg 48:340–350PubMed

37.

Cella DF, Tulsky DS, Gray G et al (1993) The functional assessment of cancer therapy (FACT) scale: development and validation of the general version. J Clin Oncol 11:570–579CrossRef

38.

Weitzner MA, Meyers C, Gelke CK, Byrne KS, Cella DF (1995) The functional assessment of cancer therapy (FACT) scale: development of a brain subscale and revalidation of the FACT-G in the brain tumor population. Cancer 75:1151–1161CrossRef

39.

Meyers C, Geara F, Wong PF, Morrison W (2000) Neurocognitive effects of therapeutic irradiation for base of skull tumors. Int J Radiat Oncol Biol Phys 46(1):51–55CrossRef

40.

Meyers C (1997) Issues of quality of life in neuro-oncology. Hand Clin Neurol 23(67):389–409

Titel: Management considerations for malignant tumors of the skull base
verfasst von: Franco DeMonte
Publikationsdatum: 09.10.2020
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2020
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-020-03637-y

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Reconstruction after endoscopic surgery for skull base malignancies

Reconstruction after open surgery for skull-base malignancies

Temporal bone resection for lateral skull-base malignancies

Quality of life considerations for patients with anterior and central skull base malignancies

Radiation therapy strategies for skull-base malignancies